Genome Biologics develops therapies for cardiovascular and cardiometabolic diseases, utilizing AI-driven big data analysis for precision preclinical and in vivo disease models.

Genome Biologics

Biotechnology Research

Genome Biologics | 1,261 followers on LinkedIn. Accelerated Drug Development | Genome Biologics identifies viable drug candidates and FDA approved drug repositioning compounds for Cardiovascular and Cardiometabolic disease. Capitalising on the power of our patented Artificial Intelligence (AI) driven preclinical multi-modality drug testing technology - We leverage the power of AI-based machine learning with transformative single cell in vitro and in vivo transgenesis to dramatically reduce the cost, time, and ethical burden of preclinical research in the pharmaceutical industry.

Professor at Goethe-Universität Hospital Frankfurt a. Main

Jaya Krishnan

Head of Research and Drug Discovery at Genome Biologics

Ting Yuan

🚀 Exciting News! 🚀 Genome Biologics is thrilled to announce an exclusive commercialization partnership with InSphero AG! This collaboration grants InSphero global rights to our revolutionary 3D Cardiac Organoid Platform, TrueCardium®. Together, we aim to set a new standard in cardiac disease research and therapeutic development. By combining our cutting-edge organoid technology with InSphero’s expertise, we're paving the way for faster, more accurate 𝐜𝐚𝐫𝐝𝐢𝐨𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐦𝐨𝐝𝐞𝐥𝐬. Stay tuned for more updates as we embark on this groundbreaking journey! 🌟 💡 #Innovation #Biotech #CardiacResearch #Organoids #Partnership #GenomeBiologics #InSphero

📣 BREAKING NEWS 📣 Genome Biologics are honored to be selected for this year's Startup Pitch & Partner Program at #BioVaria ! We look forward to presenting Genome Biologics and connecting with fellow enterpreneurs and broader life science community. At Genome Biologics , we are commited to disrupting and revolutionalising treatments for heart disease and tackling the larger burden of cardiovascular disease in the EU. 👉👉👉 Join us for discussions at #BioVaria and learn about our drug pipeline – with special focus on cardioinflammatory disorder - including clonal hematopoiesis of indeterminate potential (CHIP) #lifescience #cardio #drugpipeline

Viewport Meta

IPhone / Mobile Compatible

Euro

Apple Mobile Web Clips Icon

GoDaddy CDN

GoDaddy Website Builder

Co-founder & CTO

Jonathan Ward

Co-founder & CEO

Pharmaceutical Companies With More Than $1M in Revenue (Top 10K)

Germany Pharmaceutical Companies

Europe Therapeutics Companies

Germany Companies With Fewer Than 1000 Employees (Top 10K)

Genome Biologics are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to accelerate development of RNAi therapies to treat illnesses where no other treatments have proven effective or ever existed.

European Innovation Council

Venture Round - Genome Biologics

Grant - Genome Biologics

EASME - EU Executive Agency for SMEs

Hessen

Sachsen-Anhalt

Germany

Europe

Macedonia

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 12, 2024 4:56 AM	dff36704
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 12, 2024 4:56 AM	b93554a6
crunchbase trigger	general	Nov 12, 2024 4:56 AM	63f84f5c
crunchbase profile	general	Nov 12, 2024 11:00 AM	62806acd
li profile	general	Nov 12, 2024 4:56 AM	6d3ae903
translate crunchbase fundingrounds	general	Nov 12, 2024 11:36 AM	41fbf2f0
peers	general	Nov 12, 2024 4:56 AM	ad20e90f
news basic	general	Nov 12, 2024 4:56 AM	8a48975d
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

GENO

COM:GENOMEBIOLOGICS

Genome Biologics